Date of Award
2026-05-01
Degree Name
Master of Science
Department
Chemistry
Advisor(s)
Amol Kulkarni
Abstract
Glioblastoma multiforme (GBM) is an aggressive brain tumor with rapid progression and poor prognosis. Although temozolomide (TMZ) remains a central component of standard therapy, its clinical benefit is limited and resistance frequently emerges through DNA repair pathways, particularly O6-methylguanine-DNA methyltransferase (MGMT). Because DNA cross-links are generally more difficult to repair than monoalkylated lesions, we hypothesized that TMZ derivatives bearing protein-reactive functionality might generate damage that is less susceptible to MGMT-mediated resistance. Guided by this rationale, we designed a new class of N3-modified TMZ derivatives containing covalent warheads, developed a synthetic route compatible with the chemical instability of the TMZ scaffold, and identified Z68 as a lead compound. Z68 showed substantially improved antiproliferative activity relative to TMZ in TMZ-resistant T98G cells while retaining strong activity in U87 cells. In cell-cycle studies, TMZ produced the expected G2/M arrest in U87 cells, whereas Z68 caused little to no detectable cell-cycle arrest in either U87 or T98G cells, suggesting a mechanism distinct from that of TMZ and classical DNA-DNA cross-linking agents. Quantitative proteomic profiling in U87 cells further indicated that Z68 induces a response pattern different from those of TMZ, MTZ, and KL-50, with selective modulation of nutrient-sensing, mitochondrial-stress, and kinase-associated pathways rather than broad proteome disruption. Together, these findings identify Z68 as a promising TMZ-derived scaffold for overcoming GBM resistance and support a distinct, but still putative, mechanism of action that warrants further biochemical validation. Overall, this study introduces a promising class of TMZ-derived alkylating agents for glioblastoma and establishes a foundation for future validation of their proposed mechanism and therapeutic potential.
Language
en
Provenance
Received from ProQuest
Copyright Date
2026-05
File Size
67 p.
File Format
application/pdf
Rights Holder
Hualin Zhang
Recommended Citation
Zhang, Hualin, "Overcoming Glioblastoma Resistance To Temozolomide With New Derivatives: Design, Synthesis, And Mechanistic Studies" (2026). Open Access Theses & Dissertations. 4829.
https://scholarworks.utep.edu/open_etd/4829